Literature DB >> 7179208

Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis.

G Andersson, B Fagrell, K Holmgren, H Johnsson, B Ljungberg, E Nilsson, S Wilhelmsson, S Zetterquist.   

Abstract

One-hundred and forty-one patients with clinical signs of acute deep venous thrombosis (DVT) in the legs were randomly allocated to receive heparin either as two daily subcutaneous injections (s.c.) or as continuous intravenous infusion (i.v.). The thrombi extended into the popliteal or femoral veins in 83% of the patients. Verification of diagnosis and evaluation of therapy was performed by phlebography, plethysmography and thermography. The results showed that heparin administered s.c. twice daily was as efficient as continuous i.v. infusion in preventing extension of the thrombus. In two patients the s.c. administration was stopped due to local haematomas at the injection sites. Retroperitoneal or intramuscular bleedings occurred in four patients, two in each group. Two major, non-fatal pulmonary emboli occurred, one in each group.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7179208     DOI: 10.1016/0049-3848(82)90001-9

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

Review 1.  Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.

Authors:  Lindsay Robertson; James Strachan
Journal:  Cochrane Database Syst Rev       Date:  2017-02-14

2.  Anticoagulants in venous thromboembolism.

Authors:  M D Stringer; N Wilson; V V Kakkar
Journal:  BMJ       Date:  1989-01-21

3.  Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial.

Authors:  M G Walker; J W Shaw; G J Thomson; J G Cumming; M L Thomas
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-09

4.  Guidelines on the prevention, investigation and management of thrombosis associated with pregnancy. Maternal and Neonatal haemostasis Working Party of the Haemostasis and Thrombosis Task.

Authors: 
Journal:  J Clin Pathol       Date:  1993-06       Impact factor: 3.411

Review 5.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 6.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

7.  Heparin 1986. Indications and effective use.

Authors:  P Ockelford
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

8.  Subcutaneous versus intravenous administration of heparin in the treatment of deep vein thrombosis; which do patients prefer? A randomized cross-over study.

Authors:  A M Robinson; K A McLean; M Greaves; K S Channer
Journal:  Postgrad Med J       Date:  1993-02       Impact factor: 2.401

Review 9.  Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism.

Authors:  R L Bick
Journal:  Drugs       Date:  2000-09       Impact factor: 11.431

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.